TY - JOUR
T1 - Factors predicting reduced antidepressant response
T2 - Experience with the SNRI duloxetine in patients with major depression
AU - Howland, Robert H.
AU - Wilson, Michael G.
AU - Kornstein, Susan G.
AU - Clayton, Anita H.
AU - Trivedi, Madhukar H.
AU - Wohlreich, Madelaine M.
AU - Fava, Maurizio
PY - 2008/11
Y1 - 2008/11
N2 - Background: To identify putative demographic and clinical variables that correlate with antidepressant response to the SNRI duloxetine in major depression. Methods: The effect of 130 candidate treatment outcome predictors was examined on 3 dependent treatment outcome measures related to depression: 1) depression symptom outcome measured by HAMD-17 total and HAMD-17 percent change from baseline to endpoint, 2) remission (HAMD-17 ≤ 7 at endpoint) and response (≥ 50% reduction in HAMD-17 from baseline to endpoint) rates, and 3) time to response (days to ≥ 50% reduction in HAMD-17). Results: Eleven variables had an overall predictive index of ≥ 20% and were associated with poorer treatment outcome: HAMD-17 total, duration of current MDD episode, leaden paralysis, fatigue, HAMA total, HAMA items 2 and 8, HAMD-17 anxiety/somatization subscale, anxiety-related comorbid conditions, and VAS overall pain and pain while awake. Conclusions: Our results highlight the clinical relevance of more severe and/or persistent levels of depression, psychiatric and medical comorbidity, and symptoms characteristic of atypical depression (leaden paralysis and fatigue) and confirm findings from other studies that such patients may respond less well or take longer to respond to pharmacotherapy. Consistent with previous SNRI studies, we found no significant association between age, gender, and race/ethnicity and treatment outcome.
AB - Background: To identify putative demographic and clinical variables that correlate with antidepressant response to the SNRI duloxetine in major depression. Methods: The effect of 130 candidate treatment outcome predictors was examined on 3 dependent treatment outcome measures related to depression: 1) depression symptom outcome measured by HAMD-17 total and HAMD-17 percent change from baseline to endpoint, 2) remission (HAMD-17 ≤ 7 at endpoint) and response (≥ 50% reduction in HAMD-17 from baseline to endpoint) rates, and 3) time to response (days to ≥ 50% reduction in HAMD-17). Results: Eleven variables had an overall predictive index of ≥ 20% and were associated with poorer treatment outcome: HAMD-17 total, duration of current MDD episode, leaden paralysis, fatigue, HAMA total, HAMA items 2 and 8, HAMD-17 anxiety/somatization subscale, anxiety-related comorbid conditions, and VAS overall pain and pain while awake. Conclusions: Our results highlight the clinical relevance of more severe and/or persistent levels of depression, psychiatric and medical comorbidity, and symptoms characteristic of atypical depression (leaden paralysis and fatigue) and confirm findings from other studies that such patients may respond less well or take longer to respond to pharmacotherapy. Consistent with previous SNRI studies, we found no significant association between age, gender, and race/ethnicity and treatment outcome.
KW - Clinical trial
KW - Depression
KW - Duloxetine
KW - Predictors
KW - Response
UR - http://www.scopus.com/inward/record.url?scp=57049148576&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=57049148576&partnerID=8YFLogxK
U2 - 10.1080/10401230802437639
DO - 10.1080/10401230802437639
M3 - Article
C2 - 19034753
AN - SCOPUS:57049148576
SN - 1040-1237
VL - 20
SP - 209
EP - 218
JO - Annals of Clinical Psychiatry
JF - Annals of Clinical Psychiatry
IS - 4
ER -